Office Of Translational Sciences Putting Pieces In Motion, Dir. Murphy Says
Executive Summary
Although FDA's Office of Translational Sciences is up and running, the organizational advantages of the new office, such as centralizing Critical Path activities, continue to be inhibited by a lack of resources
You may also be interested in...
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
FDA’s Drug Center Reorganization Creates Second Safety Director Position
The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety